LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "cangrelor" as a keyword



Photo by gcalebjones from unsplash

Parenteral Antiplatelet Agents in Three Patients Receiving VA-ECMO Support to Maintain Drug-Eluting Stent Patency

Sign Up to like & get
recommendations! Published in 2021 at "Journal of Heart and Lung Transplantation"

DOI: 10.1016/j.healun.2021.01.2124

Abstract: Introduction The following cases summarize three patients administered intravenous (IV) antiplatelet therapy during their venoarterial-extracorporeal membrane oxygenation (VA-ECMO) support with successful maintenance of drug-eluting stent (DES) patency. Case Report A 36-year-old male was cannulated for… read more here.

Keywords: patient; antiplatelet; day; cangrelor ... See more keywords
Photo by jan_huber from unsplash

Inhibition of GPR17 with cangrelor improves cognitive impairment and synaptic deficits induced by Aβ1-42 through Nrf2/HO-1 and NF-κB signaling pathway in mice.

Sign Up to like & get
recommendations! Published in 2021 at "International immunopharmacology"

DOI: 10.1016/j.intimp.2021.108335

Abstract: The accumulation of amyloid beta (Aβ) in the brain is thought to be associated with cognitive deficits in Alzheimer's disease (AD). However, current methods to combat Aβ neurotoxicity are still lacking. G protein-coupled receptor 17… read more here.

Keywords: synaptic deficits; nrf2 signaling; cangrelor; impairment ... See more keywords
Photo from wikipedia

Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.

Sign Up to like & get
recommendations! Published in 2017 at "Journal of the American College of Cardiology"

DOI: 10.1016/j.jacc.2016.10.055

Abstract: BACKGROUND Cangrelor, an intravenous, reversible P2Y12 antagonist, is approved for use in patients undergoing percutaneous coronary intervention (PCI). OBJECTIVES This study sought to evaluate the efficacy and safety of cangrelor compared with clopidogrel in subgroups… read more here.

Keywords: patients undergoing; cangrelor; percutaneous coronary; coronary intervention ... See more keywords
Photo by nci from unsplash

Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.

Sign Up to like & get
recommendations! Published in 2018 at "Journal of the American College of Cardiology"

DOI: 10.1016/j.jacc.2018.07.041

Abstract: The intravenous P2Y12 receptor antagonist cangrelor provides rapid onset and offset of platelet inhibition [(1)][1]. Compared with clopidogrel, cangrelor has significantly reduced the rate of ischemic events, including stent thrombosis, during percutaneous coronary intervention (PCI),… read more here.

Keywords: ticagrelor loaded; cangrelor; cangrelor ticagrelor; percutaneous coronary ... See more keywords
Photo by dariusbashar from unsplash

Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial.

Sign Up to like & get
recommendations! Published in 2019 at "Resuscitation"

DOI: 10.1016/j.resuscitation.2019.02.008

Abstract: AIMS Cangrelor has a potentially favorable pharmacodynamic profile in cardiogenic shock (CS). We aimed to evaluate the clinical course of CS patients undergoing percutaneous coronary intervention (PCI) treated with cangrelor. METHODS AND RESULTS We retrospectively… read more here.

Keywords: oral p2y12; iabp shock; cangrelor; cardiogenic shock ... See more keywords
Photo by goian from unsplash

Effect of P2Y12 inhibitors on thrombus stability and endogenous fibrinolysis.

Sign Up to like & get
recommendations! Published in 2019 at "Thrombosis research"

DOI: 10.1016/j.thromres.2018.11.023

Abstract: Although used routinely to reduce thrombotic events in patients with coronary disease, the effects of P2Y12 inhibitors on thrombus stability and endogenous fibrinolysis are largely unknown. Blood taken from patients pre- and post-aspirin (n = 20) and… read more here.

Keywords: thrombus stability; ticagrelor; pre post; cangrelor ... See more keywords
Photo from wikipedia

Cardiac Surgery Successfully Managed With Cangrelor in a Patient With Persistent Anti-PF4/Heparin Antibodies 8 Years After Heparin-Induced Thrombocytopenia.

Sign Up to like & get
recommendations! Published in 2019 at "Journal of cardiothoracic and vascular anesthesia"

DOI: 10.1053/j.jvca.2019.06.044

Abstract: A 66-YEAR-OLD female requiring cardiac surgery had persisting anti-platelet factor 4 (PF4)/heparin antibodies (HIT-abs) 8 years after heparin-induced thrombocytopenia (HIT). In 2010, she developed thrombotic thrombocytopenic purpura (TTP) (ADAMTS-13 read more here.

Keywords: heparin antibodies; heparin; pf4 heparin; cardiac surgery ... See more keywords
Photo from wikipedia

Cangrelor for the treatment of patients with Arterial Thrombosis

Sign Up to like & get
recommendations! Published in 2018 at "Expert Opinion on Pharmacotherapy"

DOI: 10.1080/14656566.2018.1506767

Abstract: ABSTRACT Introduction: All oral P2Y12 receptor blockers are associated with some degree of delayed onset and offset of pharmacodynamic (PD) effects in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). Although intravenous… read more here.

Keywords: treatment; treatment patients; cangrelor; patients arterial ... See more keywords
Photo by towfiqu999999 from unsplash

Efficacy and safety of low dose intravenous cangrelor in a consecutive cohort of patients undergoing neuroendovascular procedures

Sign Up to like & get
recommendations! Published in 2023 at "Journal of NeuroInterventional Surgery"

DOI: 10.1136/jnis-2023-020094

Abstract: Background Cangrelor is an intravenous P2Y12 inhibitor with rapid onset and fast offset of antiplatelet action. Dose adjusted cangrelor based on platelet function testing is suggested to be advantageous for use during neuroendovascular procedures. In… read more here.

Keywords: cangrelor; neuroendovascular procedures; dose intravenous; efficacy safety ... See more keywords
Photo from wikipedia

Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION

Sign Up to like & get
recommendations! Published in 2022 at "Circulation: Cardiovascular Interventions"

DOI: 10.1161/circinterventions.121.011069

Abstract: Background: In randomized trials, cangrelor reduced periprocedural ischemic events related to percutaneous coronary intervention without increasing GUSTO severe bleeding. However, some antiplatelet agents have shown a differential treatment effect by body mass index (BMI). Methods:… read more here.

Keywords: cangrelor; platelet inhibition; cangrelor versus; obese patients ... See more keywords
Photo by nampoh from unsplash

Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety

Sign Up to like & get
recommendations! Published in 2019 at "Annals of Pharmacotherapy"

DOI: 10.1177/1060028018824640

Abstract: Objective: To review the efficacy and safety of perioperative administration of intravenous (IV) antiplatelet agents as a substitute for oral P2Y12 inhibitors and to provide clinicians guidance on optimal and cost-effective use of these medications.… read more here.

Keywords: efficacy safety; perioperative bridging; antiplatelet; cangrelor ... See more keywords